Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more "Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopaHopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approvalMore than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fl